New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a ...

In a registry of patients who underwent transcatheter aortic valve replacement, those who had single antiplatelet therapy ...

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms.

The FDA approved Edwards Lifesciences Corp.'s Sapien 3 platform for patients with asymptomatic severe aortic stenosis.

Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients ...

Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for treatment of severe ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis ...

The agency’s decision for the balloon-expandable Sapien 3 platform is based on groundbreaking results from EARLY TAVR.

Findings from the Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry demonstrate that ...

The two companies have entered into a strategic partnership to exclusively commercialize Braile’s Transcatheter Aortic Valve Implantation (TAVI) technology across Europe, India, and other ...

the KONECT RESILIA aortic surgical valve conduit, the MITRIS RESILIA mitral surgical valve and the SAPIEN 3 Ultra RESILIA transcatheter aortic heart valve. Edwards’ INSPIRIS RESILIA and SAPIEN 3 Ultra ...

the KONECT RESILIA aortic surgical valve conduit, the MITRIS RESILIA mitral surgical valve and the SAPIEN 3 Ultra RESILIA transcatheter aortic heart valve. Edwards’ INSPIRIS RESILIA and SAPIEN 3 ...